EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 109 filers reported holding EAGLE PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.93 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $21,602 | +69.9% | 1,370 | +109.5% | 0.00% | – |
| Q2 2023 | $12,712 | +797.1% | 654 | +1208.0% | 0.00% | – |
| Q1 2023 | $1,417 | +41.7% | 50 | -5.7% | 0.00% | – |
| Q4 2022 | $1,000 | 0.0% | 53 | -5.4% | 0.00% | – |
| Q3 2022 | $1,000 | -75.0% | 56 | -42.9% | 0.00% | – |
| Q2 2022 | $4,000 | -20.0% | 98 | 0.0% | 0.00% | – |
| Q1 2022 | $5,000 | -70.6% | 98 | -70.1% | 0.00% | – |
| Q4 2021 | $17,000 | -10.5% | 328 | -3.8% | 0.00% | – |
| Q3 2021 | $19,000 | +35.7% | 341 | 0.0% | 0.00% | – |
| Q2 2021 | $14,000 | -17.6% | 341 | -20.5% | 0.00% | – |
| Q1 2021 | $17,000 | -15.0% | 429 | +4.6% | 0.00% | – |
| Q4 2020 | $20,000 | +33.3% | 410 | -0.2% | 0.00% | – |
| Q3 2020 | $15,000 | +25.0% | 411 | +58.1% | 0.00% | – |
| Q2 2020 | $12,000 | +9.1% | 260 | +18.7% | 0.00% | – |
| Q1 2020 | $11,000 | – | 219 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 121,014 | $5,377,000 | 1.78% |
| Smith, Graham & Co., Investment Advisors, LP | 232,343 | $10,323,000 | 1.28% |
| GLOBEFLEX CAPITAL L P | 73,205 | $3,252,000 | 0.79% |
| SummerHaven Investment Management, LLC | 18,604 | $827,000 | 0.56% |
| BRANDES INVESTMENT PARTNERS, LP | 464,292 | $20,628,000 | 0.50% |
| Capital Impact Advisors, LLC | 11,728 | $521,000 | 0.48% |
| Watershed Asset Management, L.L.C. | 5,756 | $256,000 | 0.32% |
| Foundry Partners, LLC | 84,325 | $3,747,000 | 0.23% |
| Summit Global Investments | 33,738 | $1,499,000 | 0.13% |
| SCOUT INVESTMENTS, INC. | 147,034 | $6,533,000 | 0.13% |